BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24414704)

  • 21. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 23. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IS THE AMPLIFICATION OF c-MYC, MLL AND RUNX1 GENES IN AML AND MDS PATIENTS WITH TRISOMY 8, 11 AND 21 A FACTOR FOR A CLONAL EVOLUTION IN THEIR KARYOTYPE?
    Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
    Tsitol Genet; 2015; 49(3):25-32. PubMed ID: 26214902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
    Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
    Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature.
    Mossner M; Hopfer O; Nowak D; Baldus CD; Neumann U; Kmetsch A; Benlasfer O; John T; Perka C; Thiel E; Hofmann WK
    Exp Hematol; 2010 Aug; 38(8):661-5. PubMed ID: 20399247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.
    Gough SM; Chung YJ; Aplan PD
    PLoS One; 2012; 7(5):e36876. PubMed ID: 22606303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.
    Xu H; Menendez S; Schlegelberger B; Bae N; Aplan PD; Göhring G; Deblasio TR; Nimer SD
    Blood; 2012 Oct; 120(15):3089-97. PubMed ID: 22927245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.
    Chung YJ; Robert C; Gough SM; Rassool FV; Aplan PD
    Leuk Res; 2014 Jan; 38(1):95-102. PubMed ID: 23958061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.
    Taskesen E; Havermans M; van Lom K; Sanders MA; van Norden Y; Bindels E; Hoogenboezem R; Reinders MJ; Figueroa ME; Valk PJ; Löwenberg B; Melnick A; Delwel R
    Blood; 2014 May; 123(21):3327-35. PubMed ID: 24668493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
    Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
    Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Yang L; Wen XM; Guo H; Yang J; Deng ZQ; Qian J
    Cancer Med; 2017 Jan; 6(1):267-274. PubMed ID: 27891827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analyses of DAPK1 methylation in AML and MDS.
    Claus R; Hackanson B; Poetsch AR; Zucknick M; Sonnet M; Blagitko-Dorfs N; Hiller J; Wilop S; Brümmendorf TH; Galm O; Platzbecker U; Byrd JC; Döhner K; Döhner H; Lübbert M; Plass C
    Int J Cancer; 2012 Jul; 131(2):E138-42. PubMed ID: 21918973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel retroviral mutagenesis screen identifies prognostic genes in RUNX1 mediated myeloid leukemogenesis.
    Rae DT; Hocum JD; Bii V; Deeg HJ; Trobridge GD
    Oncotarget; 2015 Oct; 6(31):30664-74. PubMed ID: 26384344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy.
    Lao Z; Ding LW; Sun QY; Jia L; Yan B; Ng AY; Capinpin SM; Wang R; Ying L; Chng WJ; Koeffler HP; Koh WP; Yuan JM; Yang H; Goh YT; Grigoropoulos N
    Clin Cancer Res; 2024 May; 30(10):2170-2180. PubMed ID: 38437679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
    Harada H
    Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
    [No Abstract]   [Full Text] [Related]  

  • 39. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
    Stosch JM; Heumüller A; Niemöller C; Bleul S; Rothenberg-Thurley M; Riba J; Renz N; Szarc Vel Szic K; Pfeifer D; Follo M; Pahl HL; Zimmermann S; Duyster J; Wehrle J; Lübbert M; Metzeler KH; Claus R; Becker H
    Br J Haematol; 2018 Sep; 182(6):830-842. PubMed ID: 29974943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.